Table 2 Characteristics of propensity score matched patients (model 1).
Group | Case | Age at baseline | Sex | Complicated allergy | Immuno-suppressants | PSL dose | Minimum PSL dose | Corticosteroid-free remission, months | IgE, U/mL | Infection, irregular corticosteroid reduction, or malignancy | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline, mg | After the study, mg (PSL dose on relapse, mg) | Baseline, mg | After the study, mg | |||||||||
Treatment (model 1) | 1 | 62 | F | AR | MZR | 1 | 0 | 1 | 0 | 42 | 620 | |
2 | 41 | M | AD, As | 1 | relapse (0) | 1 | 0 | relapse (7) | 12 | |||
3 | 45 | M | AD, D | CyA | 10 | relapse (0.5) | 0 | 0 | relapse | 1438 | Bladder cancer, bronchiolitis | |
4 | 30 | M | AR, F | CyA | 2 | 0 | 0 | 0 | 33 | 746 | ||
5 | 51 | F | AD, S | 0.5 | 0 | 0 | 0 | 37 | 182 | |||
6 | 38 | M | AR | 2 | 0 | 1 | 0 | 29 | 721 | |||
7 | 44 | M | AD | MZR, CyA | 1 | 0 | 0.5 | 0 | 35 | |||
8 | 39 | F | AD, AR, D, F | Tac | 10 | relapse (0) | 0 | 0 | relapse (13) | 33 | Herpes zoster virus, influenza | |
9 | 54 | M | AR, S | 10 | 0 | 0 | 0 | 25 | ||||
10 | 32 | F | AD, AR, S | 3 | 0 | 2 | 0 | 37 | 1366 | |||
11 | 82 | F | AD, D | 8 | 0 | 4 | 0 | 37 | 93 | Herpes zoster virus | ||
12 | 43 | M | AD, AR | 1.66 | 0 | 1.33 | 0 | 24 | 1937 | |||
13 | 65 | F | AR | CyA | 3 | 0 | 0 | 0 | 41 | 1430 | Rectum adenocarcinoma | |
Control (model 1) | 14 | 57 | M | D | CyA | 2 | 0 | 0 | 0 | 43 | ||
15 | 63 | M | AR, U | 4 | 0 | 0 | 0 | 14 | ||||
16 | 40 | F | D, F | CyA | 8 | relapse (7) | 3.5 | 3.5 | relapse | Cervical cancer | ||
17 | 76 | M | As | CyA | 0 | 0 | 0 | 0 | 60 | 1190 | pyelonephritis | |
18 | 64 | F | AR | 0.5 | 0 | 0.33 | 0 | 41 | 770 | |||
19 | 47 | F | AD | 0 | 0 | 0 | 0 | 60 | 1050 | |||
20 | 41 | M | As | CyA | 1.5 | relapse (1) | 0.25 | 0.25 | relapse | 2186 | Rectum adenocarcinoma | |
21 | 85 | M | S | 1.5 | 1.5 | 0 | 0 | on PSL | 181 | |||
22 | 34 | M | As | CyA | 10 | relapse (9) | 0 | 0 | relapse | |||
23 | 19 | M | AR | 10 | relapse (5) | 0 | 0 | relapse | 1650 | |||
24 | 42 | M | D | CyA | 10 | relapse (9) | 10 | 9 | relapse | 345 | ||
25 | 43 | M | U | 3 | 2 | 0 | 0 | on PSL | 195 | |||
26 | 56 | F | AR, D | CyA | 2.5 | 0 | 0 | 0 | 54 | 220 | ||
